Figma Shares Indicated To Open $105/$110
On Wednesday, Stifel analysts provided insights into the market uptake of new treatments for congenital adrenal hyperplasia (CAH), following discussions with leading physicians in the field. The feedback on Crenessity, a drug used to treat CAH, was cautiously optimistic, with physicians prescribing the medication but waiting to see its early effects before increasing usage. The analysts noted that the projections for Crenessity’s adoption in pediatrics were slightly more conservative than previous estimates, with around 40% market penetration expected in approximately two years. However, the expectations for adult uptake were more positive, as adult patients are believed to be more proactive in seeking treatment.
The commentary on CRNX’s atumeletant, another drug for CAH, was generally favorable, although the initial number of prescriptions (TRx) is small, indicating a cautious start. This early feedback suggests a measured but optimistic outlook for atumeletant’s future performance in the market.
In a separate note, Stifel analysts adjusted their expectations for Neurocrine Biosciences (NASDAQ:NBIX), specifically for their first-quarter sales estimates of Ingrezza, a treatment for tardive dyskinesia. The revision aligns with the company’s conservative stance expressed at recent investor conferences. Despite the cautious outlook, InvestingPro data shows NBIX maintains robust financials with 24.8% revenue growth over the last twelve months and a "GREAT" overall financial health score. The stock currently trades near its 52-week low of $105.17, potentially presenting an opportunity as InvestingPro analysis indicates the stock is undervalued. For detailed insights and 8 additional ProTips about NBIX, including its aggressive share buyback program, check out the comprehensive Pro Research Report available on InvestingPro.
The discussions with Drs. Mitchell Geffner from the Children’s Hospital LA/USC, Ahmed Khattab from Sinai, and Ian Marshall from Rutgers provided Stifel with a clearer picture of the CAH treatment landscape. The analysts’ commentary underscores the importance of real-world usage patterns and physician experiences in shaping market expectations for new pharmaceutical products. With analyst consensus remaining bullish and price targets suggesting significant upside potential, investors seeking deeper analysis can access NBIX’s complete financial metrics and valuation models through InvestingPro.
The updates from Stifel follow a pattern of careful analysis of drug uptake and market performance, which is critical for investors and stakeholders in the biotechnology sector. As these treatments continue to be prescribed and monitored, further insights will likely emerge, informing future projections and market strategies.
In other recent news, Neurocrine Biosciences announced promising results from a study on INGREZZA, a treatment for tardive dyskinesia (TD). The study, presented at the 2025 Psychiatry Update Conference, showed that 59.2% of participants achieved remission of TD symptoms after 48 weeks. Meanwhile, RBC Capital Markets adjusted its outlook on Neurocrine Biosciences, lowering the price target to $139 due to increased payer coverage stringency affecting INGREZZA. Deutsche Bank (ETR:DBKGn) also began coverage on the company, assigning a Hold rating with a price target of $138, reflecting a cautious stance on future growth.
In addition, Neurocrine Biosciences has launched a Phase 1 clinical trial for NBI-1140675, a new VMAT2 inhibitor aimed at treating neurological conditions. This follows their recent FDA-approved treatments in the same category. The company also announced a $500 million share repurchase program, following the completion of a $300 million accelerated program. These developments indicate a continued focus on expanding their treatment portfolio and managing capital allocation effectively.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.